CCL26 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CCL26 gene in the HAP1 cell line. This product contains a heterogeneous pool of cells with disrupted CCL26 loci, generated by CRISPR/Cas9-mediated gene editing. The polyclonal format provides a robust loss-of-function model without clonal artifacts, suitable for functional genomics and signaling studies.
The HAP1 cell line is a near-haploid human chronic myelogenous leukemia (CML) cell line widely used for haploid genetic screens and CRISPR-based functional investigations. Its stable near-haploid karyotype simplifies genotype-phenotype analyses, as a single allele disruption can produce a complete loss of function. The CML origin also provides a cancer-relevant context for studying signaling pathways.
CCL26 encodes eotaxin-3, a CC chemokine that acts as a chemoattractant for eosinophils, basophils, and Th2 cells by binding to the CCR3 receptor. CCL26 expression is upregulated by IL-4 and IL-13 through activation of JAK1 and STAT6, and can also be induced by TNF and IL1B. Upon secretion, CCL26 engages CCR3, leading to phosphorylation of ERK1/2 (MAPK1), p38 MAPK, and AKT1, which drive chemotactic and inflammatory responses. CCL26 also interacts with glycosaminoglycans to form haptotactic gradients. These molecular interactions place CCL26 at the center of allergic inflammation.
The HAP1-based CCL26 knockout model allows precise dissection of chemokine signaling in a near-haploid background. Disruption of CCL26 eliminates CCR3-mediated functional outputs, enabling studies of IL-4/IL-13-STAT6 pathway dependency, alternative chemokine compensation, and crosstalk. The polyclonal nature is advantageous for high-throughput screening and drug target validation, particularly for inhibitors targeting JAK/STAT, MAPK, and AKT pathways, without clonal bias.
This product supports applications in allergic disease modeling (asthma, eosinophilic esophagitis, atopic dermatitis, allergic rhinitis), functional genomics, immune cell trafficking, and drug discovery. Compatible techniques include chemotaxis, calcium flux, and phospho-STAT6 assays, as well as RT?qPCR, ELISA, western blot, flow cytometry, and immunofluorescence. For further information, please contact Ascent Research.
